Inventor · disambiguated record
Jun Ma
Also filed as: MA JUN · Ma jun-yi
45 granted patents·19 pending applications·246 citations·filing 2009–2025
97Inventor score
Files withENANTA PHARM INC37HARBIN INST TECHNOLOGY12MA JUN4OR YAT SUN2SUZHOU NEOLOGICS BIOSCIENCE CO LTD2
Top patents by PatentIndex Score
64 records- 0198US11560368B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Jan 24, 2023·6 cites·18 claims
- 0298US11384090B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted Jul 12, 2022·14 cites·15 claims
- 0398US10683279B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 16, 2020·13 cites·18 claims
- 0497US10988458B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 27, 2021·7 cites·23 claims
- 0597US9085599B22′allene-substituted nucleoside derivativesOR YAT SUN·Filed 2012·Granted Jul 21, 2015·45 cites·21 claims
- 0695US10450301B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Oct 22, 2019·11 cites·20 claims
- 0795US10246439B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 2, 2019·12 cites·20 claims
- 0894US12018017B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Jun 25, 2024·1 cites·14 claims
- 0994US11834436B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Dec 5, 2023·2 cites·5 claims
- 1094US10450306B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Oct 22, 2019·7 cites·22 claims
- 1194US10253018B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 9, 2019·10 cites·26 claims
- 1294US10034893B25, 6-D2 uridine nucleoside/tide derivativesENANTA PHARM INC·Filed 2014·Granted Jul 31, 2018·34 cites·19 claims
- 1394US8846638B2Macrocyclic nucleoside phosphoramidate derivativesENANTA PHARM INC·Filed 2013·Granted Sep 30, 2014·34 cites·22 claims
- 1491US8648037B2Macrocyclic proline derived HCV serine protease inhibitorsOR YAT SUN·Filed 2011·Granted Feb 11, 2014·12 cites·255 claims
- 1588US10080743B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·4 cites·22 claims
- 1687US10080742B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·24 claims
- 1787US9220748B2Macrocyclic proline derived HCV serine protease inhibitorsENANTA PHARM INC·Filed 2014·Granted Dec 29, 2015·6 cites·15 claims
- 1885US10149835B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 11, 2018·2 cites·18 claims
- 1985US10080741B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·19 claims
- 2085US9169141B2Water treatment method by catalyzing ozone with a persulfateMA JUN·Filed 2012·Granted Oct 27, 2015·8 cites·18 claims
- 2184US12459923B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Nov 4, 2025·0 cites·12 claims
- 2282US10689391B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 23, 2020·2 cites·22 claims
- 2381US11008304B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2019·Granted May 18, 2021·1 cites·6 claims
- 2480US10144729B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 4, 2018·2 cites·20 claims
- 2579US2020270303A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2019·Application pending·0 cites
- 2676US11034684B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 15, 2021·1 cites·22 claims
- 2774US10138228B2Isoxazole derivatives as FXR agonists and methods of use therofENANTA PHARM INC·Filed 2017·Granted Nov 27, 2018·1 cites·18 claims
- 2873US10829486B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Nov 10, 2020·1 cites·21 claims
- 2972US10597391B2Urea-containing isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Mar 24, 2020·1 cites·25 claims
- 3071US12384753B217-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Aug 12, 2025·0 cites·6 claims
- 3170US2025376452A117-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofENANTA PHARM INC·Filed 2025·Application pending·0 cites
- 3268US11198619B2Method for efficiently preparing ferrate based on nascent interfacial activityHARBIN INST TECHNOLOGY·Filed 2019·Granted Dec 14, 2021·0 cites·14 claims
- 3368US9463990B2Water treatment agent for removing contaminant through oxidation with highly-active manganese (V) intermediateJIANG JIN·Filed 2012·Granted Oct 11, 2016·1 cites·20 claims
- 3467US2019263860A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2018·Application pending·0 cites
- 3566US12122832B2TIM-3-targeting antibodies and uses thereofSUZHOU NEOLOGICS BIOSCIENCE CO LTD·Filed 2023·Granted Oct 22, 2024·0 cites·16 claims
- 3665US2025277033A1Tim-3-targeting antibodies and uses thereofSUZHOU NEOLOGICS BIOSCIENCE CO LTD·Filed 2024·Application pending·0 cites
- 3765US2025154163A1Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 InhibitorsENANTA PHARM INC·Filed 2024·Application pending·0 cites
- 3865US2018162905A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2017·Application pending·0 cites
- 3963US2023242426A1Method of Removing Organic Pollutants in Water by Zero-Valent Iron Enhanced HypochloriteHARBIN INST TECHNOLOGY·Filed 2022·Application pending·0 cites
- 4062US2017088583A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2016·Application pending·0 cites
- 4161US2023416268A1Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitorsENANTA PHARM INC·Filed 2023·Application pending·0 cites
- 4260US8858827B2Water treatment agent for removing pollutant by reinforcing potassium permanganate with intermediate manganesMA JUN·Filed 2009·Granted Oct 14, 2014·2 cites·10 claims
- 4360US2025346506A1Membrane-Mediated Electro-Oxidation-Reduction Deep Water Treatment Device and its Operation Method ThereofHARBIN INST TECHNOLOGY·Filed 2023·Application pending·0 cites
- 4459US11976084B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted May 7, 2024·0 cites·16 claims
- 4559US11560324B2Method for removing heavy metal pollutants in water with divalent manganese strengthened ferrateHARBIN INST TECHNOLOGY·Filed 2018·Granted Jan 24, 2023·0 cites·10 claims
- 4659US2016145298A1Macrocyclic proline derived hcv serine protease inhibitorsENANTA PHARM INC·Filed 2015·Application pending·0 cites
- 4758US10196279B2Method for efficiently preparing ferrate based on nascent interfacial activityHARBIN INST TECHNOLOGY·Filed 2015·Granted Feb 5, 2019·0 cites·2 claims
- 4858US2024238733A1Preparation Method for Hollow Fiber Inorganic MembraneHARBIN INST TECHNOLOGY·Filed 2022·Application pending·0 cites
- 4957US12285747B2Method of utilizing humic acid to prepare layered humic acid/manganese oxide composite catalyst and its method of use thereofHARBIN INST TECHNOLOGY·Filed 2023·Granted Apr 29, 2025·0 cites·6 claims
- 5057US2025249412A1Method of Preparing Flexible Ceramic Membrane by Combining Manganese Oxide with Layer-by-Layer Assembly TechnologyHARBIN INST TECHNOLOGY·Filed 2025·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jun Ma files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →